Project Grant R21EB038495
Award Date 8/1/26
Completion Date 5/31/29
Dollars Obligated $195K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Oregon Health & Science University $657,007 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a multiscale approach to controlling cellular interactions in premalignant tissues. The project aims to use physical science methods to manipulate interactions between multiple cell types in precancerous tissues to restore normal tissue function. The recipient will...
- The National Cancer Institute awarded Oregon Health & Science University $1,042,004 on March 26, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a microphysiological bone metastasis-on-a-chip platform that models prostate cancer metastasis into vascularized and innervated bone tissue. The research platform incorporates a mineralized, osteocyte-embedded bone matrix supporting active osteoclast and osteoblast remodeling, perfusable pericyte-supported vasculature to...
- The National Cancer Institute awarded Oregon Health & Science University $1.312 million on July 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a patient-derived intestinal organoid system modeling gastrointestinal toxicity associated with immune checkpoint inhibitors used in cancer treatment. The funded work will develop air-liquid interface organoid cultures preserving epithelial and immune components from human colon mucosa to model immune-related adverse...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Oregon Health & Science University $216,822 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to define the PARP14 interactome in RIG-I activated colorectal cancers. The research explores how RIG-I, a cellular RNA sensor, activates immune responses against colorectal cancer when triggered by synthetic viral RNA nucleic acids. Preliminary studies show that PARP14...
- The National Cancer Institute awarded Oregon Health & Science University $638,532 on July 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on antigen immunodominance in regulation of anti-tumor CD8 T cell immunity and immunotherapy response. The research establishes antigen immunodominance as a novel therapeutic axis for predicting, modulating, and exploiting CD8 T cell responses to cancer. Cancer immunotherapies that activate CD8 T cells show promise...
- Federal Project Grant Award Summary Oregon Health & Science University received a $2.49 million Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on August 15, 2025, with a completion date of July 31, 2029. The award supports development and validation of fluorescence-guided surgery (FGS) technology to enable real-time nerve visualization during colorectal cancer surgical procedures. The project addresses a...
- The National Institute of Biomedical Imaging and Bioengineering awarded $579,935 to the University of Oregon on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a synthetic biology toolkit for use in animal models. The recipient will create a comprehensive platform for synthetic biology using the nematode Caenorhabditis elegans, including a flexible toolbox of synthetic zinc finger and dCas9-derived...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded Providence Health & Services – Oregon $1,431,420 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct spatiotemporal molecular elucidation of radiation-induced tumor microenvironment remodeling to enhance immunotherapy in head and neck cancer. The award funds research into neoadjuvant immunoradiotherapy combining checkpoint inhibition with hypofractionated...
- The National Cancer Institute awarded The Leland Stanford Junior University $163,999 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop cost-effective, user-friendly, and high-throughput microfluidic organ-on-a-chip models that recreate the human bone marrow and bone microenvironments to study breast cancer metastasis to bone. The research will investigate how bone-forming osteoblasts and bone endothelial cells facilitate the extravasation and early...
- The National Cancer Institute awarded the Research Institute At Nationwide Children's Hospital $146,779 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate metastatic tumor microenvironmental mechanisms in osteosarcoma and develop novel therapeutic approaches. The funded research identifies mechanisms underlying metastatic establishment in osteosarcoma by examining interactions between epithelial cells, macrophages, and tumor cells within the...